The Law Firm of Levi & Korsinsky, LLP Announces Investigation of Anadys Pharmaceuticals Inc.

Levi & Korsinsky is investigating the Board of Directors of Anadys Pharmaceuticals Inc. (“Anadys” or the “Company”) (NASDAQ: ANDS) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Roche Holding AG. Under the terms of the transaction, Anadys shareholders will receive $3.70 in cash per share of Anadys stock they own. The transaction is valued at approximately $230 million.

Click here to learn more about the investigation: http://zlk.9nl.com/anadys-pharmaceuticals/, or call: 877-363-5972.

The investigation concerns whether the Anadys Board of Directors breached their fiduciary duties to Anadys stockholders by failing to adequately shop the Company before entering into this transaction and whether Roche Holding AG is underpaying for Anadys shares, thus unlawfully harming Anadys stockholders. Roche has said that the proposed acquisition would boost its own portfolio of hepatitis C drugs, which include Pegasys and Copegus. While the deal is priced at $3.70 per share, at least one analyst has set a price target for the stock of $4.00 per share.

If you own common stock in Anadys and wish to obtain additional information, please contact Joseph E. Levi, Esq. either via email at [e-mail] or by telephone at [phone], toll-free: [phone], or visit http://www.zlk.com.

Levi & Korsinsky has expertise in prosecuting investor securities litigation and extensive experience in actions involving financial fraud and represents investors throughout the nation, concentrating its practice in securities and shareholder litigation. The attorneys at Levi & Korsinsky have been appointed by numerous courts throughout the country to serve as lead counsel on behalf of shareholders in major litigations involving mergers and acquisitions. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.